Baiyunshan: Subsidiary drugs enter pivotal clinical trials.

Announcement from Baiyunshan: The selective RET small molecule inhibitor BYS10 developed by Baiyunshan Pharmaceutical General Factory branch has recently received feedback from the National Medical Products Administration Drug Evaluation Center. BYS10 tablets are mainly used for the treatment of advanced solid tumors such as non-small cell lung cancer and medullary thyroid cancer, with a research and development investment of 146 million RMB. CDE has agreed for BYS10 tablets to apply for market approval through a phase II single-arm clinical trial in the future, and currently, only two RET inhibitors, Pralsetinib and Selpercatinib, have been approved for market launch worldwide.